Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.71 |
| ▸ | BACE1 | P56817 | 3/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 6/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29652026 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL5527841 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL29381442 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL31294294 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL29378933 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL18093398 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL29378754 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL29928591 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL18093396 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 | |
| SCHEMBL4472768 | 1.00 | APP (0.71) | APPBACE1PTPN1MAOBIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915333-B1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSM IP ASSETS BV (NL) | 2015-06-03 | — | — | EP | disclosed |
| US-7601877-B2 | Condensation of a prenol or isoprenol with a hydroquinone or derivative in the presence of 0.005-1.0 mol percent of a Bronsted or Lewis acid catalyst selected from a bismuth, indium or Group 3 chloride, a heteropolyacid, and an NH- or a CH-acidic compound, oxidizing the ubihydroquinone; improved kinetics | DSM IP ASSETS B.V. (NL) | 2009-10-13 | — | — | US | disclosed |
| US-20080275275-A1 | Process for the Preparation of Ubihydroquinones and Ubiquinones | DSM IPASSETS B.V. (NL) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275275-A1 | Process for the Preparation of Ubihydroquinones and Ubiquinones | UBE2D3, UBE2L3, UBE2I | APP 3845/4885BACE1 3565/4885PTPN1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.